The Centers for Disease Control and Prevention (CDC) reported on Mar. 25 that its surveillance systems have detected the emerging SARS-CoV-2 BA.3.2 variant across multiple countries, including early signals in United States wastewater samples.
The findings are significant because they show how traveler screening and wastewater monitoring can provide early warnings about new variants of concern, allowing public health officials to track the spread and evolution of the virus more effectively.
According to the CDC's latest Morbidity and Mortality Weekly Report, the BA.3.2 variant was first identified in South Africa in November 2024 and has since been reported in 23 countries, with detections rising since September 2025. In the U.S., detections include four travelers' nasal swabs, five clinical specimens from patients, three airplane wastewater samples, and over one hundred thirty wastewater surveillance samples from twenty-five states.
The CDC said that "as SARS-CoV-2 has continued to circulate, the virus has accumulated spike protein mutations that may affect transmissibility, immune escape, and vaccine effectiveness." The agency uses a multimodal genomic surveillance system integrating international reports with U.S.-based sampling to monitor these changes.
The report details how digital population health data—including sequences uploaded to open-access databases such as NCBI and GISAID—were analyzed alongside preprint studies, media reports, GitHub repositories, traveler-based genomic surveillance (TGS), national clinical sequencing programs (NS3), and national wastewater surveillance systems (NWSS). These efforts allow researchers to map variant prevalence by country and week using statistical methods based on collection dates up through February 11.
BA.3.2 was initially found in a respiratory sample from a child in South Africa before being identified in Mozambique, several European countries including Germany and the Netherlands—and eventually detected among travelers arriving in the United States by June 2025 via TGS monitoring at airports.
In Europe during late 2025 into early 2026 nearly thirty percent of weekly variant sequences were attributed to BA.3.2 sublineages within certain countries like Germany or Denmark; however overall infection rates remained stable during this period according to sequence data collected internationally.
U.S.-based clinical cases included both children treated as outpatients as well as older adults hospitalized with comorbidities—all surviving their infections so far according to available records through February of this year; meanwhile phylogenetic analysis revealed two main subvariants circulating globally: BA.3.2.1 & BA.3.2.2 reflecting ongoing viral evolution worldwide.
Although laboratory research suggests that BA.3.2 is capable of evading antibodies generated by prior infection or current vaccines used for COVID-19 prevention there is not yet evidence suggesting increased severity among those infected domestically or abroad—with all documented patients recovering thus far according to CDC analyses released this week.
The agency concluded that continued genomic monitoring combined with observational studies on vaccine performance will be necessary moving forward "to guide public health strategies" amid ongoing viral evolution.
